# A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

> **NCT06720038** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vaxcyte, Inc.** · enrollment: 900 (actual)

## Conditions studied

- Pneumococcal Vaccines

## Interventions

- **BIOLOGICAL:** 0.5 mL of the low dose VAX-31
- **BIOLOGICAL:** 0.5 mL of the mid dose VAX-31
- **BIOLOGICAL:** 0.5 mL of the high dose VAX-31
- **BIOLOGICAL:** 0.5 mL dose of PCV20
- **BIOLOGICAL:** 0.5 mL of the High-PFS dose VAX-31

## Key facts

- **NCT ID:** NCT06720038
- **Lead sponsor:** Vaxcyte, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 900 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06720038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06720038, "A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06720038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*